Drug Trial Radar · NCT02052310
Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants
Last checked: Nov 19, 2026Latest source record: Oct 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,043
Actual
Start
Feb 11, 2014
Primary completion
Sep 21, 2018
Study completion Sep 21, 2018
Sponsor
- Lead sponsor
- Kyntra BioIndustry
- Sponsor type
- Industry
- Collaborators
- Astellas Pharma Europe B.V.; AstraZeneca
- First posted
- Feb 3, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether roxadustat is safe and effective in the treatment of anemia in participants who have just begun dialysis treatment for ESRD.
Conditions
- Anemia in Incident Dialysis Patients
Interventions
RoxadustatDrug
Roxadustat will be administered per dose and schedule specified in the arm.
Epoetin AlfaDrug
Epoetin alfa will be administered TIW according to the epoetin alfa USPI or SmPC, or local SOC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- US (FDA) Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Week 28 to Week 52), Regardless of Rescue Therapy (ITT Population)Time frame: Baseline (Day 1, Week 0), Week 28 to 52
- Ex-U.S. Submission: Hb Responder Rate- Percentage of Participants Who Achieved a Hb Response at 2 Consecutive Visits at Least 5 Days Apart During First 24 Weeks of Treatment, Without Rescue Therapy Within 6 Weeks Prior to the Hb Response (PPS Population)Time frame: Baseline (Day 1, Week 0) up to Week 24
Locations
113 sites in 15 countries. Site status is shown where the registry gives one.
Investigational Site
Chula Vista, California
Investigational Site
La Mesa, California
Investigational Site
San Diego, California
Investigational Site
Coral Springs, Florida
Investigational Site
Lauderdale Lakes, Florida
Investigational Site
Miami, Florida
Investigational Site
Miami, Florida
Investigational Site
Tampa, Florida
Meridian
Meridian, Idaho
Investigational Site
Shreveport, Louisiana
Investigational Site
Detroit, Michigan
Investigational Site
Pontiac, Michigan
Investigational Site
Brookhaven, Mississippi
Investigational Site
Columbus, Mississippi
Investigational Site
Gulfport, Mississippi
Investigational Site
Tupelo, Mississippi
Investigational Site
Saint Ann, Missouri
Investigational Site
St Louis, Missouri
Investigational Site
Portsmouth, New Hampshire
Investigational Site
Albuquerque, New Mexico
Investigational Site
Durham, North Carolina
Investigational Site
New Bern, North Carolina
Investigational Site
Columbus, Ohio
Investigational Site
Columbia, South Carolina
Investigational Site
Orangeburg, South Carolina
Investigational Site
Sumter, South Carolina
Investigational Site
Knoxville, Tennessee
Investigational Site
Edinburg, Texas
Investigational Site
Houston, Texas
Investigational Site
Houston, Texas
Investigational Site
Serandi, Buenos Aires, Argentina
Investigational Site
Santa Fe, IX Region, Argentina
Investigational Site
Burgas, Bulgaria
Investigational site
Dobrich, Bulgaria
Investigational site
Pazardzhik, Bulgaria
Investigational site
Pernik, Bulgaria
Investigational Site
Pleven, Bulgaria
Investigational Site
Plovdiv, Bulgaria
Investigational site
Rousse, Bulgaria
Investigational Site
Sofia, Bulgaria
Showing 40 of 113 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.